Enjoy complimentary customisation on priority with our Enterprise License!
The parkinsons disease (PD) drugs market share is expected to increase by USD 1.57 billion from 2019 to 2024, and the market's growth momentum will accelerate at a CAGR of 6%.
This parkinsons disease (PD) drugs market research report extensively covers parkinsons disease (PD) drugs market segmentation by geography (Europe, North America, Asia, and ROW) and drug class (DA and levodopa-carbidopa, MAO inhibitors, AChE inhibitors, glutamate inhibitors, and others). The parkinsons disease (PD) drugs market report also offers information on several market vendors, including AbbVie Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., GlaxoSmithKline Plc, Kyowa Kirin Co. Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., and UCB SA among others.
Download the Free Report Sample to Unlock the Parkinsons Disease (PD) Drugs Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The new drug launches is notably driving the parkinsons disease (PD) drugs market growth, although factors such as the entry of generics may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the parkinsons disease (PD) drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Parkinsons Disease (PD) Drugs Market Driver
One of the key factors driving growth in the parkinsons disease (PD) drugs market is the drug launches. The array of new drug approvals and the launch of new drugs by key vendors are expected to drive the growth of the PD drugs market. In September 2020, Neurocrine Biosciences Inc. launched the new medication, catechol-O-methyltransferase (COMT) inhibitor, for the treatment of PD. In January 2018, Adamas Pharmaceuticals Inc. announced the commercial launch of its flagship product, GOCOVRI (amantadine) extended-release capsules, for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. In June 2018, ACADIA Pharmaceuticals Inc. announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with Parkinson's disease psychosis. Such regulatory approvals and commercial launches of drugs for PD are expected to drive the growth of the PD drugs market.
Key Parkinsons Disease (PD) Drugs Market Trend
The gene therapy to reverse the progression of PD is a parkinsons disease (PD) drugs market trend that is expected to have a positive impact in the coming years. The understanding of the genetic origin of PD has made considerable progress during the past few decades, and consequently, several novel strategies are now being investigated to deliver the neuroprotective gene to the basal ganglia nuclei of the brain, which may halt the progression of the disease. Lentivectors is an enveloped virus that belongs to the Retroviridae family. The ability to integrate into the host genome leading to stable transgene expression makes lentivectors a desirable vector for gene transfer. Adeno-associated virus (AAV)-based viral vector is the most widely used vector in carrying out clinical trials for PD and is derived from AAV. AAV presents good safety profile, efficient transduction, and durable expression of neurons, thus, making it an ideal vector for gene transfer. Thus, the use of gene therapy technology for the development of PD drugs will boost the growth of the market.
Key Parkinsons Disease (PD) Drugs Market Challenge
The entry of generics will be a major challenge for the parkinsons disease (PD) drugs market during the forecast period. The presence of generic drugs impacts the market as the price of generic drugs is almost half the price of branded drugs. With an increase in the number of ANDA approvals, more generic drug manufacturers have entered the market, which is intensifying the competition in the market. Owing to the loss of patent, many generic drug manufacturers, such as Cipla, Mylan, and Dr. Reddy's Laboratories Ltd., have received generic drug approvals from the US FDA to market the generic drug of PD. Since several generic manufacturers have entered the market, generic drugs have become more affordable than branded drugs. Thus, the lack of branded drugs, owing to patent expiry, and the growing penetration of generic drugs in the global PD drugs market may impede the growth of the global PD drugs market.
This parkinsons disease (PD) drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2020-2024.
Technavio categorizes the global parkinsons disease (PD) drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the parkinsons disease (PD) drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the parkinsons disease (PD) drugs market encompasses successful business strategies deployed by the key vendors. The parkinsons disease (PD) drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
AbbVie Inc. - It is a combination product containing carbidopa and levodopa for the treatment of PD.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The parkinsons disease (PD) drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the parkinsons disease (PD) drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
For more insights on the market share of various regions Request for a FREE sample now!
37% of the market's growth will originate from Europe during the forecast period. Germany, Italy, UK, and Spain are the key markets for parkinsons disease (PD) drugs in Europe. Market growth in this region will be faster than the growth of the market in the Asian and North American regions.
The strong prevalence of PD and the easy availability of multiple approved drugs will facilitate the parkinsons disease (PD) drugs market growth in Europe over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The parkinsons disease (PD) drugs market share growth by the DA and levodopa-carbidopa segment will be significant during the forecast period. The DA and levodopa-carbidopa segment dominated the global PD drugs market with the highest market share in 2019. The high market share is attributed to increased therapeutic benefits of this drug class, which, in turn, leads to the high adoption rate of these drugs among general physicians.
This report provides an accurate prediction of the contribution of all the segments to the growth of the parkinsons disease (PD) drugs market size and actionable market insights on post COVID-19 impact on each segment.
|
Parkinsons Disease (PD) Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2019 |
|
Forecast period |
2020-2024 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6% |
|
Market growth 2020-2024 |
$ 1.57 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
4.97 |
|
Regional analysis |
Europe, North America, Asia, and ROW |
|
Performing market contribution |
Europe at 37% |
|
Key consumer countries |
US, Germany, Japan, Italy, UK, Spain, and China |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
AbbVie Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Eisai Co. Ltd., GlaxoSmithKline Plc, Kyowa Kirin Co. Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., and UCB SA |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Drug Class
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
